» Articles » PMID: 11346874

Predictive Value of Grade for Metastasis Development in the Main Histologic Types of Adult Soft Tissue Sarcomas: a Study of 1240 Patients from the French Federation of Cancer Centers Sarcoma Group

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2001 May 11
PMID 11346874
Citations 226
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Histologic grade is said to be the most important prognostic factor in adult soft tissue sarcomas (STS), but most grading systems have been tested in the overall sarcoma group and the predictive value of histologic grade needs to be assessed specifically for each of the histologic categories.

Methods: From 1980 to 1994, 1240 nonmetastatic patients were entered in the French STS database. The following parameters were studied: patient's age and gender, previous history, tumor location, size and depth, neurovascular or bone involvement (NBI), histologic type and subtype, and grade (the French Federation of Cancer Centers [FNCLCC] system). Median follow-up for the survivors was 88 months; only 5% of patients were lost to follow-up. The authors performed univariate and multivariate analyses for metastasis-free survival for the overall sarcoma group and for every main histologic type.

Results: In order of importance, parameters were respectively retained as independent predictors of metastasis as follows: grade, tumor size, NBI and tumor depth for the overall group, grade and NBI for malignant fibrous histiocytomas (n = 349), tumor size, histologic subtype and grade for liposarcomas (n = 188), NBI, grade and tumor size for leiomyosarcomas (n = 148), grade and NBI for synovial sarcomas (n = 125), grade for unclassified sarcomas (n = 140), and sarcomas of other types (n = 158). No parameter was significant for malignant schwannomas (n = 72) or for rhabdomyosarcomas (n = 60).

Conclusion: In this study, histologic grade appeared as an independent predictor of metastasis development in the main histologic types of adult STS, with the exception of malignant schwannomas and rhabdomyosarcomas.

Citing Articles

Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?.

Paudel A, Chattopadhyay P, Rose B, Watson A, DAmato G, Trent J Cancers (Basel). 2025; 17(5).

PMID: 40075735 PMC: 11898467. DOI: 10.3390/cancers17050889.


Analysis of demographics and treatment outcomes for gastrointestinal leiomyosarcoma based on the SEER database.

Bao Y, Yang X, Zhao Q, Li W Sci Rep. 2025; 15(1):7761.

PMID: 40044719 PMC: 11882819. DOI: 10.1038/s41598-025-91758-7.


Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.

Roets E, Younger E, Jones R, Hollander D, Desar I, Young R Support Care Cancer. 2025; 33(3):228.

PMID: 40011242 PMC: 11865148. DOI: 10.1007/s00520-025-09248-5.


Evaluation of sarcopenia's relationship with overall survival and treatment toxicity in soft tissue sarcomas.

Onur I, Akdur P, Firat H, Camoz E, Ciledag N, Savran B Support Care Cancer. 2025; 33(3):167.

PMID: 39921759 DOI: 10.1007/s00520-025-09235-w.


Evaluating ChatGPT-4o as a decision support tool in multidisciplinary sarcoma tumor boards: heterogeneous performance across various specialties.

Ammo T, Guillaume V, Hofmann U, Ulmer N, Buenting N, Laenger F Front Oncol. 2025; 14:1526288.

PMID: 39896191 PMC: 11782276. DOI: 10.3389/fonc.2024.1526288.